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I n t roduct ion  
The prevention and treatment of infectious diseases 
has been one of the major successes in medicine. 
Nevertheless, the need for new and improved vac- 
cines remains as great as ever and the search for new 
antimicrobial agents and intensification of treatment 
with existing drugs continues because many infec- 
tions can not be treated adequately with the estab- 
lished drugs and treatment methods. 
For almost 200 years vaccines have consisted of 
whole micro-organisms, killed or live but attenuated. 
Many of these vaccines have been highly successful, 
with perhaps the vaccinia virus for smallpox as the 
most striking example. Several compelling reasons 
exist, however, for limiting the number of antigens in 
a vaccine to those which are protective. It may be 
desirable to avoid the inclusion of genetic material 
and toxic components of the microorganism. It may 
be necessary to circumvent the strategy used by the 
micro-organism to evade the immune system. The 
search for new vaccines, i.e. those composed of sub- 
units of micro-organisms, either purified from natural 
sources or produced by recombinant DNA tech- 
niques or by chemical synthesis, has been aided by 
advances in molecular biochemistry and by under- 
standing the factors regulating the immune re- 
sponse. Unfortunately, these subunit vaccines are 
not, or only weakly, immunogenic in the absence of 
an immunological adjuvant. 
From clinical experience, it is well known that in 
immunocompromised patients infections are still a 
major cause of morbidity and mortality. The number 
of immunocompromised patients is growing and 
includes patients with malignant diseases treated 
with intensive chemotherapy, organ and bone mar- 
row transplant recipients receiving immunosuppress- 
ive treatment, and patients with the acquired im- 
munodeficiency syndrome (AIDS). One of the factors 
that contribute to treatment failure is an impaired 
host defence system unable to provide adequate 
support for antibiotic therapy. Improvement of the 
treatment of severe infections in immunocom- 
promised patients is urgently required. 
One approach to increase the immunogenicity of 
purified microbial antigens and to potentiate the 
therapeutic action of antimicrobial agents is to 
employ liposomes as vehicles for their delivery [I-3]. 
Liposomes are membrane-like vesicles consisting of 
one or more phospholipid bilayers surrounding 
aqueous compartments (Fig. I). Hydrophobic agents 
can be embedded in the lipid bilayers and hydro- 
philic agents can be entrapped in the internal 
aqueous space of the liposomes. The charge, rigidity, 
size, and surface properties of liposomes can be 
varied and controlled by incorporating different 
types of lipids and by varying the preparation 
method. The fate of liposomes as well as the encap- 
sulated agent in the body is primarily dependent on 
these parameters (charge, rigidity, size and surface 
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Schematic representation of a multilamellar liposome. 
In an aqueous environment he phospholipids orient 
themselves in bilayers with their headgroups directed 
towards the water molecules and the acyl chains 
isolated from the water phase. Water-soluble molecules 
can be entrapped in the internal aqueous space and 
lipid-soluble molecules can be incorporated in the lipid 
bilayers. Reprinted with the permission of the New 
England Journal of Medicine [4] 
properties). Therefore, liposomes are considered as 
versatile delivery systems. The potential widespread 
clinical use of liposomes, as opposed to many other 
parenteral drug delivery systems, may result from the 
fact that the lipids most often used for liposome 
preparation are those commonly found in cell mem- 
branes, and that liposomes are biodegradable, rela- 
tively nontoxic, and nonantigenic or weakly anti- 
genic [5 6]. 
After intravenous administration, the main fraction 
of almost all types of liposomes is rapidly removed 
from the blood and taken up by cells of the mono- 
nuclear phagocyte system (MPS), particularly the 
tissue macrophages in liver and spleen [7]. This 
natural tendency of liposomes to accumulate in the 
cells of the MPS can be employed for the prevention 
and treatment of infectious diseases in several ways. 
Firstly, they can be used as carriers of antibiotics for 
selective delivery to infections that localize primarily 
in the cells of the MPS. Increased intracellular anti- 
biotic concentrations may potentiate therapeutic 
activity by enhancing the delivery of drugs to the 
intracellular site of infection. Secondly, macrophages 
may be stimulated into the microbicidal state by 
liposome-encapsulated immunomodulators for the 
treatment of both intracellular and extracellular 
infections. Finally, macrophages play a key role in the 
induction of immune responses to antigens [8]. The 
liposome-mediated delivery of antigens to macro- 
phages may be one of the major factors causing lipo- 
some-associated antigens to be more immunogenic 
than the free antigen. 
The use of liposomes for the delivery of antibiotics 
to infections in non-MPS tissues requires a reduced 
initial uptake by the MPS, enabling the liposomes to 
circulate long enough to reach the infected tissues or 
cells. Prolonging the blood residence time of lipo- 
somes after intravenous administration can be 
achieved by manipulation of the physicochemical 
characteristics of the liposomes. Alternatively, the 
initial clearance of liposomes by liver and spleen can 
be avoided by injection of the vesicles into an ana- 
tomically defined compartment, which may be of 
value for local treatment of infections. 
The objective of this article is to outline the poten- 
tial application of liposomes in the field of infectious 
diseases, that is improvement of the therapeutic 
index of antimicrobial drugs and immunomodulators 
and stimulation of the immune response to other- 
wise weak antigens in vaccines composed of purified 
micro-organism subunits. As the literature available 
on this topic is abundant, attention will be focussed 
on major breakthroughs and recent developments. 
Unless stated otherwise, liposomes were of the type 
that after intravenous administration is mainly taken 
up by cells of the MPS. 
Liposome-mediated delivery of 
antimicrobial agents 
The use of liposomes as antibiotic delivery systems 
aims for: increased antibiotic concentrations at the 
site of infection, resulting from targeting the anti- 
biotic to the infected tissues; increased intracellular 
antibiotic concentrations, resulting from targeting 
the antibiotic to the infected cells; and reduced tox- 
icity of potentially toxic antibiotics, resulting from 
avoiding distribution to sites susceptible to toxicity. 
Application of liposomes may offer an excellent way 
to increase the selective delivery of antibiotics in 
these respects. The first studies on the use of lipo- 
somes as carriers of antibiotics were performed in 
models of leishmaniasis and were published in 1978 
[9 10]. Until now most experimental data were de- 
rived from studies with antibiotic-containing lipo- 
somes applied in models of infection by facultative 
and obligate intracellular pathogens localized in MPS 
cells. A variety of protozoal, viral, fungal and bac- 
terial infections was studied. 
/iposomes for the systemic treatment of 
infectious diseases 
Due to the natural behaviour of liposomes after intra- 
venous administration the encapsulated antibiotic 
will be targeted to MPS tissues, resulting in relatively 
high and prolonged intracellular concentrations of 
the antibiotic. A poor penetration into the cells and a 
decreased activity intracellularly are the major 
reasons for a limited activity of most antibiotics 
(notably the penicillins, cephalosporins and amino- 
glycosides) in intracellular infections. 
Leishmania are obligate intracellular protozoa re- 
siding within macrophages and are harboured inside 
phagolysosomes. In animal models of leishmaniasis, 
liposome-encapsulated antimonial compounds and 
liposome-encapsulated amphotericin B (including 
Amphocil | and AmBisome | were applied. In gen- 
eral, all these studies demonstrated an increase in the 
therapeutic index of the antibiotic (an increase in 
efficacy as well as a reduction of toxicity of potential- 
ly toxic antibiotics) resulting from encapsulation in 
liposomes [11]. Successful treatment of a patient 
with drug-resistant visceral leishmaniasis with AmBi- 
some | was reported in 1991 [12]. AmBisome | was 
also used for the treatment of visceral leishmaniasis 
in AIDS patients unresponsive to antimonial com- 
pounds and appeared to be effective for treatment 
and secondary prophylaxis [1 3 14]. In animal models 
of malaria (Plasmodium bergheO, the infection was 
successfully treated with liposome-encapsulated 
chloroquine even when the infectious organism was 
resistant to the free agent [15]. This could be 
ascribed to sustained release of chloroquine from the 
intraperitoneally injected liposomes. 
With respect to viral infections, it was demon- 
strated in an animal model of infection caused by Rift 
Valley fever virus which replicates in liver macro- 
phages, that liposome-encapsulated ribavirin was 
more effective than the free agent [16]. The data 
obtained from other animal studies on the efficacy of 
liposome-encapsulated antiviral agents in various 
models of viral infection, caused by herpes simplex 
virus, influenza virus, Rauscher murine leukaemia 
virus, or murine AIDS, are contradictory with respect 
to the efficacy of antiviral agent when administered 
in the liposome-encapsulated form [17-19]. Also data 
from in vitro studies in which various cell types in- 
fected with various viral strains were exposed to anti- 
viral agent in the free form or liposome-encapsulated 
form are contradictory [19-21]. In some studies anti- 
viral antibody was incorporated into liposomes. As 
liposomes can be targeted to specific cells by the 
conjugation of the appropriate antibodies to the lipid 
bilayer, they are expected to be ideal carriers for the 
delivery of drugs to virus-infected cells. For immuno- 
liposomes containing aciclovir it was demonstrated 
that these liposomes specifically bind to herpes sim- 
plex virus-infected cells in vitro, and are most effi- 
cacious in inhibiting virus replication [22]. 
Regarding fungal infections, most studies are per- 
formed with amphotericin B encapsulated in lipo- 
somes or bound to other lipid carriers with the main 
purpose of reducing the toxicity of this antifungal 
agent. Extensive studies have been performed with 
various formulations of liposomal or lipid-complexed 
amphotericin B [23]. The first study was published in 
1982 [24]. Various animal models of fungal infection 
were used, such as cryptococcosis, histoplasmosis, 
candidiasis, and aspergillosis to compare the effi- 
cacies of free amphotericin versus liposomal or lipid- 
complexed amphotericin B [25-29]. Studies were 
performed in immunocompetent as well as immuno- 
deficient animals. The studies clearly show that, in 
spite of a lower antifungal activity dependent on the 
liposome or lipid carrier, due to the decrease of tox- 
icity these amphotericin B formulations display a 
markedly increased therapeutic index. In the model 
of systemic candidiasis in immunocompetent or 
neutropenic mice the efficacy of liposomal ampho- 
tericin B bearing anticandidal antibodies was investi- 
gated, and was found to be increased compared to 
identical doses of liposomal amphotericin B [30]. 
Clinical studies with liposome-encapsulated ampho- 
tericin B have been in progress for several years. The 
first study was published in 1985 by Lopez-Berestein 
et al. [31], followed by many other publications. 
Most published clinical data on efficacy are available 
for AmBisome | showing encouraging results in a 
variety of fungal infections in immunocompromised 
patients [32]. With respect to the industrially pro- 
duced preparations AmBisome | amphotericin B lipid 
complex (ABLC), and Amphocil | it is evident that 
these have quite different structural and pharmaco- 
kinetic characteristics [33]. The clinical pharmaco- 
kinetics and safety of these formulations have been 
~nvestigated. It is not clear whether the differences in 
structure and pharmacokinetics may be important 
with regard to tolerance and efficacy. Clinical trials 
comparing these data for the various liposomal and 
lipid-complexed amphotericin B formulations are 
needed to assess their clinical value. 
In a number of models of intracellular bacterial 
infection, representative agents of various classes of 
antibiotics (aminoglycosides, penicillins, cephalo- 
sporins, quinolones) were applied in the free or lipo- 
some-encapsulated form. Particularly with respect to 
the aminoglycosides [34], which despite their tox- 
icity still have an important antimicrobial role, the 
encapsulation into liposomes may reduce the toxicity 
and, in addition, will change the pharmacokinetics of 
these agents resulting in a reduction of nephro- 
toxicity. Bacterial infections were caused by Myco- 
bacterium tuberculosis, Salmonella spp., Brucella spp., 
Listeria monocytogenes, and Mycobacterium avium 
complex [35]. These studies on the treatment of 
intracellular infections in MPS tissues clearly demon- 
strate the superior efficacy of administration in the 
liposome-encapsulated form. In most studies using 
models of mycobacterial infection in which also the 
lung was involved in the infection, an increased 
therapeutic effect of liposome-encapsulated anti- 
biotic over non-encapsulated antibiotic was only ob- 
served in the spleen, and not in the lung. However, 
in some mycobacterial infections the superior effect 
of liposome-encapsulated antibiotic was also found 
in the lung. The efficacy of liposomal gentamicin for 
the treatment of Mycobacterium avium complex 
infections in AIDS patients is under investigation 
[36]. For the targeting of liposome-encapsulated 
antibiotics to the lung, liposomes coated with amylo- 
pectin derivatives were employed in an animal model 
of Legionella pneumophila pneumonia [37]. The anti- 
biotic sisomycin that was encapsulated in these lipo- 
somes was highly effective in the treatment of the 
lung infection as a result of targeting to the infected 
tissue. 
Supplementary to the efficacy data obtained in 
models of bacterial infection, in vitro data on the role 
of liposomes in targeting antibiotics to bacterially 
infected phagocytic cells also show the superiority of 
liposome-encapsulated antibiotics. In most cases, 
monocyte or macrophage cultures were infected 
with bacterial strains such as Staphylococcus aureus, 
Brucella spp., Salmonella spp., Escherichia col/, Listeria 
monocytagenes, Chlamydia trachomatis, and 
Mycobacterium avium complex [35]. Classical lipo- 
somes were used. The infected cells were exposed to 
aminoglycosides, penicillins, cephalosporins or chlor- 
amphenicol. Also, studies were performed with 
human monocytes/macrophages infected with 
Legionella pneumophila or Mycobacterium avium com- 
plex, or polymorphonuclear leucocytes of patients 
with chronic granulomatous disease infected with 
Staphylococcus aureus. The studies show that the in- 
tracellular micro-organisms were effectively killed 
when the cells were exposed to liposome-encapsu- 
lated antibiotic, whereas the same concentration of 
non-encapsulated antibiotic alone or in combination 
with placebo liposomes did not show an antimicro- 
bial effect. It was demonstrated that by varying the 
lipid composition of the liposomes the intracellular 
degradation of the liposomes could be influenced 
and thereby the rates at which liposome-encapsu- 
lated agents were released and became available to 
exert their therapeutic action [38]. 
Animal studies on the treatment of infections by 
bacterial strains not necessarily located intracellularly 
in MPS tissues show somewhat contradictory results 
with respect to the efficacy of liposome-encapsulated 
antibiotics versus free antibiotics. An explanation for 
this is that the applicability of liposomes in the treat- 
ment of infectious diseases caused by extracellular 
micro-organisms not restricted to MPS tissues has 
been strongly limited by the preferential uptake of 
intravenously administered liposomes by cells of the 
MPS. 
Liposomes avoiding the mononuclear phagocyte 
system 
The ability to achieve a significantly longer blood 
residence time of liposomes creates new possibilities 
for improving the delivery of antibiotics to infected 
tissues in general, including infections in non-MPS 
tissues. Many years ago it was already demonstrated 
that factors contributing to the prolongation of lipo- 
some circulation times included the reduction of 
liposome size, and modification of the liposomal 
composition yielding an increased rigidity of the 
bilayer. With such liposomes, administration of rela- 
tively high lipid doses is needed to obtain a relatively 
long circulation time [7]. Later, it was observed that 
the incorporation of specific glycolipids, such as 
monosialoganglioside GM-1 and hydrogenated 
phosphatidylinositol (HPI), resulted in prolonged cir- 
culation without the constraint of high lipid doses 
but application was still limited to the use of rigid 
bilayers [39 40]. Such liposomes were named MPS- 
avoiding liposomes or Stealth | liposomes [41]. 
Importantly, it was shown that such liposomes ex- 
hibit enhanced Jocalization in a variety of implanted 
tumours in mice [42]. More recently, many reports 
have shown that the incorporation of phosphatidyl- 
ethanolamine derivatives of monomethoxy-poly- 
ethyleneglycols (PEG-PE) in the liposomal bilayer also 
enhances the blood circulation time of liposomes to 
an extent equal to or exceeding that found pre- 
viously but without the requirements of high lipid 
dose or rigid nature of the bilayers [39 43-45]. The 
term sterically stabilized liposomes has been pro- 
posed for these PEGylated liposomes. 
In our laboratory we investigated the potential of 
MPS-avoiding liposomes for the enhanced delivery of 
antibiotics to sites of bacterial infection [46 47]. An 
experimental model of unilateral pneumonia caused 
by Klebsiella pneumoniae in rats was used. Bacterial 
inoculation of the left lung resulted in a progressive 
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infection of the left lung; the right lung of the same 
animal developed no infection. Two types of MPS- 
avoiding liposomes, HPI-containing liposomes and 
PEG-PE-containing liposomes, versus one type of 
classical (short-circulating) liposomes were exam- 
ined. Circulation half-lives for HPI-containing lipo- 
somes and PEG-PE containing liposomes were 5 h 
and 20 h, respectively. The prolonged residence time 
in the bloodstream was accompanied by a relatively 
low hepatosplenic uptake. 
The degree of lung localization of liposomes was 
determined in groups of rats with varying intensity of 
infection. The experimental data, shown in Figure 2, 
indicate that liposomes with prolonged blood circu- 
lation time show substantial localization in infected 
lung tissue after intravenous administration. The 
PEG-PE-containing liposomes were clearly superior to 
the HPI-containing liposomes and reached a level of 
9% of the injected liposomal dose in severely in- 
fected rats. The increased localization of either lipo- 
some preparation in the infected left lung is likely to 
be related to the local infectious process, as in the 
right lung of the same rat (in which infection did not 
develop) the degree of localization of liposomes was 
not increased compared with the localization ob- 
served in uninfected rats. The data suggest that the 
degree of localization of liposomes in the infected 
tissue is favoured by a prolonged residence time of 
liposomes in the blood compartment, enabling the 
liposomes to reach the infected tissue more effi- 
ciently. The degree of lung localization of liposomes 
correlated with the intensity of the infection, and sig- 
nificantly increased from the moment that bacterial 
multiplication in the lung resulted in a local inflam- 
matory response. Localization of classical (short-cir- 
culating) liposomes in the infected lung tissue was 
significantly lower. 
A valuable asset of the PEG-PE-containing lipo- 
somes is that they show dose-independent pharma- 
cokinetics. Prolonged circulation of these liposomes 
is not dependent on high lipid doses. Therefore, MPS 
saturation due to high doses of liposomes, which 
may result in impaired ability to clear bacteria from 
the blood, can be avoided. This is important as for 
immunocompromised patients, in which generaliz- 
ation of the infection frequently occurs, maximal 
blood clearance capacity of the MPS is needed and 
can be maintained. In addition, the capacity of PEG- 
PE in prolonging the blood residence time of lipo- 
somes has been reported to be independent of the 
lipid composition (phase transition temperature, 
charge). In view of the difference in pharmaco- 
dynamics of different classes of antibiotics, the rate 
of release of encapsulated antibiotic from the lipo- 
somes is important for an optimum therapeutic 
effect. Manipulation of the release rate can be 
achieved by variation in the lipid composition, which 
in the case of these PEG-PE-containing formulations 
can be done without compromising the prolonged 
circulation properties. Therefore, these PEG-PE-con- 
taining liposomes show great promise for increased 
delivery of antibiotics to sites of infection. The factors 
that account for the extravasation of liposomes in 
the infected lung tissue have yet to be elucidated. 
Liposomes probably extravasate in areas of inflam- 
mation as a result of locally increased capillary per- 
meability or through injured endothelial linings 
Liposomes for the local treatment of infectious 
diseases 
The largest number of studies in this field has in- 
volved treatment of eye infections, with the aim to 
increase the availability of the encapsulated anti- 
microbial agent to the eye in terms of uptake and 
residence time compared to conventional formu- 
lations [48]. The liposomes were administered as eye 
drops or as subconjunctival or intravitreal injections. 
Literature dealing with other routes of administration 
for local treatment of infections is scarce. 
Eye drops are easy to use, but the drug tends to be 
washed away rapidly from the cornea by the tear 
fluid and by blinking. Consequently, penetration of 
the drug into ocular tissues is poor and, if pen- 
etration occurs, it provides only a short duration of 
action. Frequent administration is necessary to main- 
tain adequate drug levels. 
Smolin et al. demonstrated that a liposomal eye 
drop formulation containing idoxuridine was more 
effective for the treatment of experimental herpes 
simplex keratitis than a comparable therapeutic 
regime of idoxuridine alone [49]. The authors sug- 
gested that the beneficial effects of liposomal admin- 
istration of idoxuridine were due to improved cor- 
neal penetration of the drug and higher therapeutic 
drug levels in the virus-infected cells, although no 
direct evidence was presented. Liposomes enhanced 
the corneal flux and corneal uptake of the hydro- 
philic antibiotic benzylpenicillin [50], while ocular 
distribution studies in the rabbit eye indicated that 
absorption of another hydrophilic antibiotic, di- 
hydrostreptomycin sulfate, was significantly impaired 
by liposome administration [51]. In conclusion, al- 
though some therapeutic results have been reported, 
the advantage of delivery of liposome-encapsulated 
antimicrobial agents in eye drop formulations is not 
clear. 
Another approach to obtain a high drug level in 
the cornea is to inject the drug subconjunctivally. 
However, the free drug is rapidly removed from the 
subconjunctival depot, providing limited drug bio- 
availability. Liposomal gentamicin was found to give 
higher gentamicin levels in the sclera and cornea up 
to 24 h after injection [52]. In a model of keratitis 
caused by Pseudomonas aeruginosa, a single subcon- 
junctival administration of liposome-encapsulated 
tobramycin was significantly more effective than a 
single subconjunctival administration of the free drug 
[53]. It was nearly as effective as 24 doses of hourly 
topical fortified tobramycin. 
Intravitreal injection of antimicrobial agents has 
become a part of the standard treatment of some 
intraocular infections. Unfortunately, in many in- 
secondary to the infectious process~ In addition, stances repeated administration is needed to achieve 
phagocytosis of liposomes by inflammatory cells infil- 
trating the infected tissue may also account for 
enhanced localization of liposomes in the infected 
lung. The present results derived from the studies in 
this Klebsiella lung infection model indicate that 
MPS-avoiding liposomes are 'passively' targeted 
towards the infected tissue. The passive targeting of 
these liposomes to the sites of infection is certainly of 
great importance with respect to clinical application, 
as in immunocompromised patients the localization 
as well as the aetiology of the infection is often 
unknown. 
adequate antimicrobial concentrations for prolonged 
periods of time. Repeated injections, however, can 
be accompanied by complications, such as lens or 
retinal injury. Moreover, some antimicrobial agents 
can cause severe retinal damage. Therefore, lipo- 
somes have been explored as depot system, re- 
leasing the drug slowly, thereby reducing the toxicity 
of the drug and maintaining desired drug concen- 
trations for a prolonged period of time. It was 
demonstrated that gentamicin [54], amikacin [55], 
ganciclovir [56] and amphotericin B [57] in liposome 
formulations were cleared from the vitreous signifi- 5 
cantly more slowly than the free drug. In some cases, 
therapeutic concentrations of the antimicrobial agent 
were found in the vitreous for up to two weeks after 
injection. Residence times of the liposomal antimicro- 
bial agents were dependent on liposome size, lipo- 
some composition, and the presence and severity of 
infection [55 58]. In a model of Staphylococcus aureus 
endophthalmitis, one injection with liposome-encap- 
sulated clindamycin was demonstrated to eradicate 
the infection [59]. Unfortunately, the experimental 
set-up did not include a comparison with the antimi- 
crobial activity of the free drug, thus preventing any 
conclusion about the effect of encapsulation of the 
drug. A study of liposomal amphotericin B showed 
that a reduced toxicity of intravitreally injected lipo- 
some-encapsulated amphotericin B was accom- 
panied by a reduced antifungal activity against 
Candida albicans [60]. No major increase in the 
therapeutic index of amphotericin B was observed. 
Preliminary clinical studies indicate that some ocular 
infections, such as cytomegalovirus retinitis, acute 
toxoplasmosis, retinochoroiditis and bacterial endo- 
phthalmitis, can be managed with intravitreal admin- 
istration of liposome-encapsulated rugs [56 61]. 
Liposome-mediated elivery of 
immunomodulators 
Potentiation of the non-specific defence system with 
immunomodulating agents to improve the treatment 
of patients with severe infections is under investi- 
gation. The cells of the MPS are generally considered 
as key cells in the non-specific host defence against 
infections, and stimulation of these cells by using 
immunomodulators is of great value for the poten- 
tiation of the treatment of severe infections. Es- 
pecially immunomodulators that exert their major 
action through macrophages, such as muramyl 
dipeptide (MDP), the smallest part of the peptido- 
glycan of the cell wall of bacteria with immuno- 
modulating properties, its amphipathic derivatives, 
and interferon gamma (IFNT) have been explored. 
Although in animal models these agents in the free 
form enhance the resistance to infections and 
tumours, their use is hampered by the brief circu- 
lation time and poor distribution to the cells of the 
MPS. Therefore, frequent administration of high 
doses of these immunomodulators is required to ob- 
tain a therapeutic effect. However, this causes severe 
side effects. As liposomes are taken up preferentially 
by the cells of the MPS, targeting of immunomodu- 
lators to the MPS can be effectively accomplished by 
administration via liposomes. This so-called passive 
targeting allows lower dosages to be effective, which 
favours prolonged treatment protocols. Several 
studies have shown that administration of immuno- 
modulators in liposomes reduces the toxicity and 
changes the tissue distribution and pharmacokinetics 
of the encapsulated agent favourably [62-64]. More- 
over, immuno-neutralization and binding to serum 
proteins is reduced, because of decreased exposure 
of the agent to the body. 
As liposome-encapsuJated immunomodulators 
exert their action mainly via fixed macrophages, the 
first studies in this field were performed in intracel- 
lular infections of the cells of the MPS. It was demon- 
strated that liposome-encapsulated IFN 7 was more 
effective than the free agent in animal models of 
infection caused by Listeria monocytogenes [65] and 
Leishmania donovani [64]. These micro-organisms 
replicate primarily inside macrophages of the MPS. 
Similar results were reported for free and liposome- 
encapsulated muramyl tripeptide phosphatidyl- 
ethanolamide (MTP-PE). In vitro studies with peri- 
toneal macrophages infected with Toxoplasma gondii 
showed antitoxoplasma activity of liposome-encap- 
sulated IFN 7 [66]. With respect to suppression of 
virus replication inside macrophages of the MPS, the 
efficacy of liposome-encapsulated MTP-PE was 
studied in an infection model of Rift Valley fever virus 
[67]. This infection is characterized by multiplication 
of virus in Kupffer cells and dissemination of virus to 
the central nervous system. Significant therapeutic 
effects were observed, whereas free MDP, even at 
I00 times the dose administered in liposomes, was 
not effective. Because the monocyte/macrophage 
serves as a reservoir and vector for HIV, liposomal 
immunomodulators might also be useful in the treat- 
ment of AIDS. In vitro studies have indicated that 
liposome-encapsulated MTP-PE is a potent inhibitor 
of HIV replication in macrophages [68]. It should be 
noted, however, that some viruses show enhanced 
replication in activated macrophages [69]. Thus, 
when the antiviral activity of a liposome-encapsu- 
lated immunomodulator is studied, it is important to 
analyse the ability of the virus to replicate in acti- 
vated macrophages prior to examining in vivo anti- 
viral therapeutic effects. 
Exposure of cells in vitro to two or more agents at 
the same time is easy to achieve. However, in vivo it 
is unlikely that two agents injected simultaneously 
will exert their effect on the same cells at the same 
time. This may be accomplished by the adminis- 
tration of the immunomodulators co-encapsulated in 
the same liposome, which will result in simultaneous 
delivery of the agents to the target cell. Treatment of 
Listeria infection with MTP-PE and IFN T in the same 
liposome resulted in an enhanced antimicrobial 
resistance [65]. Synergism between liposomal MTP- 
PE and IFNTwas also shown in a Leishmania infection 
model [64] and in tumour models [70]. 
Besides the treatment of intracellular infections of 
the cells of the MPS with liposomal immunomodu- 
lators, extracellular infections and intracellular infec- 
tions of non-phagocytic cells have been studied. In 
an experimental model of an infection caused by 
Klebsiella pneumoniae, a bacterium that is poorly 
taken up by the cells of the MPS, it was shown that 
after prophylactic treatment with liposomal MTP-PE 
or IFN~ about 65% of the mice survived from an 
otherwise lethal disseminated infection [71]. Admin- 
istration of MTP-PE and IFN 7 co-encapsulated in lipo- 
somes resulted in an increased efficacy of treatment, 
with 100% survival of the infected mice [unpub- 
lished observations of our own]. Other investigators 
showed that the MDP derivative N-acetylmuramyl-L- 
~-aminobutyryl-D-isoglutamine (Abu-MDP) encapsu- 
lated in liposomes is a potent stimulator of the 
resistance to Candida albicans infections [72]. 
Macrophages have been shown to play an import- 
ant role in the control of virus infections of non- 
phagocytic cells. Activated macrophages acquire the 
ability to lyse selectively virus-infected cells without 
harming normal cells. Intravenous administration of 
employing liposomal immunomodulators, only 
prophylactic treatment proved to be effective, 
whereas therapeutic treatment did not show benefi- 
cial effects on tumour growth or the course of infec- 
tion. In one study it even seemed that therapeutic 
treatment acted negatively on the host defence [71]. 
When injected in high dosages, liposomes might 
blockade the phagocytic capacity of macrophages, 
resulting in a decreased clearance of micro-organ- 
isms. Nevertheless, the limited number of animal 
studies available indicate that prophylactic treatment 
with liposome-encapsulated immunomodulators 
might be useful in patients who are at high risk to 
develop severe infections. 
liposome-encapsulated MTP-PF was reported to sig- 
nificantly protect mice against intranasal infection 
with herpes simplex virus type 1 [73] and against 
intravenous and intraperitoneal infections with 
herpes simplex virus type 2 [74]. Activation of alveo- 
lar macrophages and Kupffer cells, respectively, by 
liposome-encapsulated MTP-PE was assumed to 
enhance their antiviral capacity and consequently 
virus growth was inhibited. 
The activity of liposomal TNFc~, a macrophage- 
derived cytokine which is important in the cascade 
leading to the activation of the host defence system 
against infections, was examined. Liposomal encap- 
sulation resulted in a reduction of the toxicity of this 
cytokine. However, treatment of mice with liposome- 
encapsulated TNFc~ did not induce significant antimi- 
crobial effects against infections with Mycobacterium 
avium and Klebsiella pneumoniae [75; unpublished 
observations of our own]. Although synergy between 
TNFc~ and IFN~' was shown in vitro [76], adminis- 
tration of these cytokines co-encapsulated in lipo- 
somes did not result in a significantly enhanced host 
defence against Klebsiella pneumoniae septicaemia 
[unpublished observations of our own]. 
Animal studies performed in the field of cancer 
immunotherapy showed a beneficial effect of the 
application of liposome-encapsulated immunomodu- 
lators on the eradication of micrometastases. Recent 
clinical studies in cancer patients revealed that treat- 
ment with liposomal MTP-PE doses between 2.0 and 
4.0 mg/m 2 (biweekly) induces only minor side-effects 
(fever, chills, malaise, hypertension and nausea) [77 
78]. An increase in white blood cell count, granulo- 
cytes, interleukin-6 serum levels, TNFc~ and neopterin 
was observed in these patients, indicating macro- 
phage activation [77-80]. In most animal studies 
Liposome-mediated delivery of microbial 
antigens in vaccines 
Aluminum salts are presently the only immunological 
adjuvant licensed for use in vaccines for humans, but 
are far from ideal: they do not potentiate cell- 
mediated immunity, they are not always effective 
and they are not entirely free of undesired reactions 
at the injection site. The emergence of new-gener- 
ation recombinant subunit and synthetic peptide 
vaccines has renewed demands for novel adjuvants 
that are both acceptable and effective in potentiating 
humoral as well as cell-mediated immunity. 
The first description of liposomes as vehicles of 
antigens to augment antibody responses appeared in 
1974 [81]. Since then, the efficacy of liposomes as 
vehicles for the presentation of antigens to the 
immune system has been shown for a variety of bac- 
terial, viral and protozoal antigens. In contrast to 
many other vehicles, liposome-associated antigens 
do not induce granulomas at the injection site and 
hypersensitivity reactions are generally not observed. 
Macrophages have been proposed to serve as the 
predominant antigen-presenting cells in the induc- 
tion of immune responses by liposomal antigens [2]. 
After internalization of the liposomes, antigens re- 
leased from the liposomes are processed in the lyso- 
somal compartment of the macrophage, transported 
to the cell membrane and presented to CD4 § T- 
helper cells in the context of major histocompatibility 
complex (MHC) class II molecules [82 83]. This lipo- 
some-mediated delivery of antigens to macrophages 
may be one of the major factors causing liposome- 
associated antigens to be more immunogenic than 
the free antigens. However, direct interaction of lipo- 
somal antigens with lymphocytes and a slow release 
of antigens from depots at the injection site may play 
a role as well. 
Liposomes are versatile vehicles in terms of struc- 
tural characteristics and mode of antigen encapsu- 
lation. This creates a wide range of options for the 
design of effective liposomal antigen formulations to 
induce humoral and cell-mediated immunity. In 
Table 1 factors are presented that have been shown 
to affect the immune response to liposome-associ- 
ated antigens. Such factors may influence the in vivo 
behaviour of liposomes and their interactions with 
cells. In spite of much research, considerable contro- 
versy surrounds the relationship between liposomal 
properties and their efficacy as vehicles for antigens. 
For instance, opposite views have been expressed 
with regard to the role of liposomal membrane 
Toxins/toxoids 
Cholera toxin 
Diphtheria toxoid 
Tetanus toxoid 
Protozoal antigens 
Leishmania mexicana surface antigen gp63 and lipophosphoglycan 
Leishmania major soluble antigens 
Nippostrongylus brasiliensis antigens 
Plasmodium falciparum merozoite surface antigens 
Plasmodium falciparum sporozoite recombinant protein and synthetic 
peptide 
Toxoplasma gondii membrane protein 
Viral antigens 
Adenovirus type 5 hexon and fiber proteins 
Encephalomyocarditis virus (inactivated) 
Simian immunodeficiency virus synthetic peptide 
*Microbial antigens shown are only those of medical or veterinary 
relevance. Adapted from Gregoriadis [85] and updated. 
fluidity and antigen localization in promoting im- 
mune responses [2 84 85]. It is likely that the physi- 
cal and chemical characteristics of liposomes that 
give optimum responses differ for various antigens. 
Consequently, characteristics of liposomes would 
have to be optimized for individual antigens. So far, 
the approach to design liposomal vaccine formu- 
lations and immunization protocols is mainly empiri- 
cal. No clear insight exists on how to prepare lipo- 
some-based vaccines with optimum immunological 
properties. In addition, little information is available 
on the efficacy of liposomes as adjuvants in the very 
young or elderly populations, immunocompromised 
subjects and genetically low responders or non- 
responders. 
Class I restricted CD8 § cytotoxic T cells (CTL) rep- 
resent a necessary component for immunity against 
viral and certain intracellular parasitic infections. 
Peptides recognized by CTL are generated by the 
proteolysis of antigens in the cytoplasm and are pre- 
sented at the cell's surface by MHC class I molecules. 
Inactivated pathogens and soluble proteins generally 
fail to prime CTL, as these antigens are processed in 
the endosomes and do not enter the MHC class I 
presentation pathway. Although it was initially 
thought that liposomes were not very effective in 
priming CD8 + CTL in vivo [86], recent studies have 
demonstrated that liposomes containing synthetic 
peptides or recombinant proteins can induce prim- 
ary, antiviral CTL responses in animal models [87- 
89]. In these studies modifications of the liposomes, 
such as coating with a mannan-derivative, inclusion 
of Quil A or a fusion protein in liposomes, were 
necessary to deliver the protein into the MHC class I 
presentation pathway. 
In many experimental situations the immunogen- 
icity of the antigen-containing liposomes was still 
limited. Therefore, immunomodulators were applied 
as adjuvants to further potentiate the immune 
response induced by liposome-encapsulated antigen. 
It is not surprising that amphipathic immunomodu- 
lators that activate macrophages have been studied 
extensively. Monophosphoryl lipid A [90 91] and 
amphipathic derivatives of MDP [90 92] in particular 
have been shown to be effective. The best effects of 
these adjuvants were usually noted when the adju- 
vant was co-encapsulated with the antigen in the 
same liposome formulation [93 94]. Recently, much 
attention has been focussed on the use of cytokines 
as adjuvants [95 96]. As these agents are rapidly 
cleared from the circulation, repeated injections are 
required to obtain strong immune responses. Encap- 
sulation of cytokines in liposomes aims mainly at 
creating a depot system for sustained release of the 
cytokine. 
Table 2 summarizes many of the microbial anti- 
gens encapsulated in liposomes for studying the 
induction of humoral and cell-mediated immunity in 
animal models. The antigens employed vary from 
whole (inactivated) viruses to highly purified anti- 
gens obtained by recombinant DNA techniques and 
synthetically prepared peptides containing B and/or 
T cell epitopes. These antigens were encapsulated in 
liposomes or covalently attached to the vesicles. In 
some studies, the liposomal antigen formulation con- 
tained immunomodulators as well. In general, prim- 
ary and secondary humoral immune responses were 
increased after encapsulation of the antigens in lipo- 
somes for all protein antigens tested for humoral 
immunity. Interestingly, in several studies it was 
shown that oral or intranasal administration 
of antigens in liposomes resulted in local secretory 
IgA levels several times higher than was elicited by 
free antigen, probably because of vesicle inter- 
action with lymphoid tissue in the gut or bronchus 
[97 98]. 
Besides humoral immunity, induction of cell- 
mediated immunity as measured by delayed-type 
hypersensitivity reactions, lymphocyte proliferation 
and CTL induction has been reported for several of 
the liposome-encapsulated antigens summarized in 
Table 2. In animal models, protection was obtained 
against infections with Mycobacterium tuberculosis, 
Salmonella typhimurium, Streptococcus spp., Leish- 
mania spp., Nippostrongylus brasiliensis, Toxoplasma 
gondii, influenza virus, Epstein-Barr virus, and herpes 
simplex virus by immunization with liposome-encap- 
sulated antigens [85]. In some of these studies, 
immunomodulators (MTP-PE, monophosphoryl lipid 
A) were co-encapsulated with the antigen into the 
liposomes to induce higher levels of protection. The 
safety and immunogenicity of a liposome-based 
malaria vaccine injected into human subjects has 
recently been reported [99]. High levels of specific 
antibody were observed. 
Conc lus ions  and f inal remarks  
Animal studies have demonstrated that several intra- 
cellular infections involving the MPS can be more 
effectively treated with liposome-encapsulated anti- 
microbial agents than with conventional formu- 
lations. The natural targeting of liposomes to the 
phagocytic cells of the MPS results in higher and pro- 
longed antibiotic concentrations at the site of infec- 
tion. With respect to toxicity, liposomes have proven 
useful for reducing the toxicity of potentially toxic 
antimicrobial agents, such as the aminoglycosides 
and amphotericin B. These promising results of pre- 
clinical studies along with technical advances in lipo- 
somal preparation techniques and efficient drug 
entrapment have led to a large number of clinical 
trials. A liposomal preparation of amphotericin B, 
AmBisome | was the first liposome preparation 
licensed on the market in several countries for intra- 
venous application. A number of other lipid-based 
amphotericin B preparations is likely to follow soon. 
Additional clinical trials are needed to assess the clini- 
cal value of these preparations and to determine the 
full spectrum of indications. 
Although the efficacy of liposomal antibiotics 
against a number of infections of the MPS has been 
clearly shown, no systemic efforts have been made 
to optimize the therapeutic effects. For instance, by 
manipulating the liposomal composition, rates of 
uptake and intracellular degradation can be influ- 
enced and thereby the rates at which liposome- 
encapsulated agents are released and become avail- 
able to exert their therapeutic action. 
The recently developed sterically stabilized lipo- 
somes open new avenues for achieving specific tar- 
geting of antibiotics to infections located outside the 
tissue macrophages of the liver and spleen. However, 
at present no studies have been reported on the 
efficacy of such liposomes in the treatment of micro- 
bial infections. 
Concerning targeting of immunomodulators to 
macrophages of the MPS by means of liposomes, 
experimental evidence is now available of the poten- 
tial usefulness of liposomes for stimulating the non- 
specific antimicrobial resistance. This approach may 
also be of importance for the potentiation of the 
treatment of severe infections. Insight into cells and 
cytokines involved in the enhanced antimicrobial 
resistance induced by liposome-encapsulated immu- 
nomodulators is needed before optimum liposomal 
dosage forms can be rationally designed. 
Liposomes have been shown to act as powerful 
immunological adjuvants for a variety of bacterial, 
viral and protozoal antigens, largely through en- 
hanced delivery to antigen-presenting cells. The 
ability to convert a poorly immunogenic antigen into 
a highly immunogenic one together with the rela- 
tively low toxicity makes liposomes attractive candi- 
dates as adjuvants in new generations of vaccines 
composed of recombinant antigens and synthetically 
prepared peptides. 
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